The CSL Ltd (ASX: CSL) share price is down 1.6% to $255.51 per share on Monday.
The ASX 200 biotech is in the red today because its shares have begun trading ex-dividend.
The CSL share price is now trading close to its 52-week low of $253.04 set on 12 February.
That trough came one day after the ASX 200 healthcare giant released its 1H FY25 report.
Meanwhile, the broader market is enjoying a green start to the week.
The S&P/ASX 200 Index (ASX: XJO) is currently up 0.21% to 7,965.1 points.
This follows a shocker for the benchmark index last week.
The ASX 200 closed at a six-month low of 7,948.2 points last Friday.
It lost 2.74% of its value over the week due to the impact of US tariffs on market sentiment.
CSL will pay a dividend of US$1.30 per share unfranked on 9 April.
The FY25 interim dividend is 9% higher than the FY24 interim dividend.
CSL will convert the dividend into AUD currency and announce the finalised dividend amount to be paid to Australian shareholders on Thursday.
Based on today's exchange rate, the US$1.30 dividend translates to AU$2.06 per share.
CSL has not released any announcements today.
The last lot of price-sensitive news from the biotech giant came on 11 February with its 1H FY25 report.
CSL reported a 5% rise in revenue in constant currency terms to US$8.48 billion for the half.
It also reported a 7% increase in net profit after tax (NPAT) in constant currency to US$2.04 billion.
The company said the main driver of revenue growth was its Behring division.
CSL Behring manufactures medicines and operates the company's plasma collection network.
CSL reported a 10% lift in Behring division revenue to US$5.74 billion.
This reflected a 15% jump in immunoglobulin product sales to US$3,174 million, a 9% increase in Albumin sales to US$672 million, and an 11% rise in Haemophilia sales to US$731 million.
Sales of specialty products fell 5%.
The CSL Seqirus business, which develops and manufactures vaccines, recorded a 9% decrease in sales to US$1.66 billion.
This partly reflects a global trend in falling immunisation rates.
Sales in CSL's Vifor division, which develops and manufactures drugs to treat iron deficiency and kidney disease, lifted 6% to US$1.08 billion.
This was driven by rising demand for iron products in Europe and higher demand for Tavneos, a drug that treats inflammatory conditions of the blood vessels, in all of CSL's markets.
The CSL share price has fallen by 9% in the year to date.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.